Topical Rapamycin Formulations

About Quoin Pharmaceuticals

Quoin Pharmaceuticals is a NASDAQ-listed company (QNRX) dedicated to addressing critical unmet medical needs in rare and orphan diseases, with a mission to 'bring hope where there is currently none.' Its innovative pipeline, centered on proprietary topical rapamycin formulations, targets severe dermatological and vascular conditions like Netherton Syndrome, Peeling Skin Syndrome, and Microcystic Lymphatic Malformations. The company has secured key regulatory designations (Orphan Drug, Rare Pediatric Disease) in the US and EU, is executing multiple clinical trials, and has built a global commercial network ahead of potential product launches.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals is a NASDAQ-listed company (QNRX) dedicated to addressing critical unmet medical needs in rare and orphan diseases, with a mission to 'bring hope where there is currently none.' Its innovative pipeline, centered on proprietary topical rapamycin formulations, targets severe dermatological and vascular conditions like Netherton Syndrome, Peeling Skin Syndrome, and Microcystic Lymphatic Malformations. The company has secured key regulatory designations (Orphan Drug, Rare Pediatric Disease) in the US and EU, is executing multiple clinical trials, and has built a global commercial network ahead of potential product launches.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals is a NASDAQ-listed company (QNRX) dedicated to addressing critical unmet medical needs in rare and orphan diseases, with a mission to 'bring hope where there is currently none.' Its innovative pipeline, centered on proprietary topical rapamycin formulations, targets severe dermatological and vascular conditions like Netherton Syndrome, Peeling Skin Syndrome, and Microcystic Lymphatic Malformations. The company has secured key regulatory designations (Orphan Drug, Rare Pediatric Disease) in the US and EU, is executing multiple clinical trials, and has built a global commercial network ahead of potential product launches.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals is a NASDAQ-listed company (QNRX) dedicated to addressing critical unmet medical needs in rare and orphan diseases, with a mission to 'bring hope where there is currently none.' Its innovative pipeline, centered on proprietary topical rapamycin formulations, targets severe dermatological and vascular conditions like Netherton Syndrome, Peeling Skin Syndrome, and Microcystic Lymphatic Malformations. The company has secured key regulatory designations (Orphan Drug, Rare Pediatric Disease) in the US and EU, is executing multiple clinical trials, and has built a global commercial network ahead of potential product launches.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals is a NASDAQ-listed company (QNRX) dedicated to addressing critical unmet medical needs in rare and orphan diseases, with a mission to 'bring hope where there is currently none.' Its innovative pipeline, centered on proprietary topical rapamycin formulations, targets severe dermatological and vascular conditions like Netherton Syndrome, Peeling Skin Syndrome, and Microcystic Lymphatic Malformations. The company has secured key regulatory designations (Orphan Drug, Rare Pediatric Disease) in the US and EU, is executing multiple clinical trials, and has built a global commercial network ahead of potential product launches.

Therapeutic Areas